ATE453645T1 - Verfahren zur herstellung von pyrrolotriazinverbindungen, die sich als kinaseinhibitoren eignen - Google Patents

Verfahren zur herstellung von pyrrolotriazinverbindungen, die sich als kinaseinhibitoren eignen

Info

Publication number: ATE453645T1
Authority: AT; Austria
Prior art keywords: sub; producing; kinase inhibitors; compounds suitable; pyrrolotriazine compounds
Prior art date: 2002-11-06

Application number

AT03781756T

Other languages

English (en)

Inventor

Jollie Godfrey

John Hynes

Alaric Dyckman

Katerina Leftheris

Zhongping Shi

Stephen Wrobleski

Wendel Doubleday

John Grosso

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-06

Filing date

2003-11-03

Publication date

2010-01-15

2003-11-03 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2010-01-15 Application granted granted Critical

2010-01-15 Publication of ATE453645T1 publication Critical patent/ATE453645T1/de

Links

229940043355 kinase inhibitor Drugs 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
150000003921 pyrrolotriazines Chemical class 0.000 title 1
238000000034 method Methods 0.000 abstract 3
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 abstract 1
SHCRKMNTWSCEBT-UHFFFAOYSA-N N1N=NC=C2N=CC=C21 Chemical group N1N=NC=C2N=CC=C21 SHCRKMNTWSCEBT-UHFFFAOYSA-N 0.000 abstract 1
108091000080 Phosphotransferase Proteins 0.000 abstract 1
238000005576 amination reaction Methods 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1
238000007363 ring formation reaction Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/50—Nitrogen atoms

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Rheumatology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pulmonology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)

AT03781756T 2002-11-06 2003-11-03 Verfahren zur herstellung von pyrrolotriazinverbindungen, die sich als kinaseinhibitoren eignen ATE453645T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/289,010 US6867300B2 (en)	2000-11-17	2002-11-06	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
PCT/US2003/035220 WO2004043912A2 (en)	2002-11-06	2003-11-03	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors

Publications (1)

Publication Number	Publication Date
ATE453645T1 true ATE453645T1 (de)	2010-01-15

Family

ID=32312096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03781756T ATE453645T1 (de)	2002-11-06	2003-11-03	Verfahren zur herstellung von pyrrolotriazinverbindungen, die sich als kinaseinhibitoren eignen

Country Status (16)

Country	Link
US (2)	US6867300B2 (de)
EP (1)	EP1562949B1 (de)
JP (1)	JP4662775B2 (de)
KR (1)	KR20050084961A (de)
CN (1)	CN100360532C (de)
AT (1)	ATE453645T1 (de)
AU (1)	AU2003287514A1 (de)
BR (1)	BR0316056A (de)
CA (1)	CA2505365A1 (de)
CO (1)	CO5560547A2 (de)
DE (1)	DE60330800D1 (de)
ES (1)	ES2337571T3 (de)
MX (1)	MXPA05004748A (de)
PL (1)	PL377112A1 (de)
TW (1)	TWI290555B (de)
WO (1)	WO2004043912A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6982265B1 (en) *	1999-05-21	2006-01-03	Bristol Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
US6867300B2 (en) *	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) *	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) *	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
US7388009B2 (en)	2002-04-23	2008-06-17	Bristol-Myers Squibb Company	Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
BR0309669A (pt) *	2002-04-23	2005-03-01	Bristol Myers Squibb Co	Compostos de anilina de pirrolo-triazina úteis como inibidores de cinase
WO2003091229A1 (en)	2002-04-23	2003-11-06	Bristol-Myers Squibb Company	Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
TW200401638A (en) *	2002-06-20	2004-02-01	Bristol Myers Squibb Co	Heterocyclic inhibitors of kinases
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
TW200420565A (en)	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
BRPI0407282A (pt)	2003-02-05	2006-01-31	Bristol Myers Squibb Co	Processo para preparação de inibidores de pirrolotriazina cinase
US7102001B2 (en)	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine
US20060014741A1 (en) *	2003-12-12	2006-01-19	Dimarco John D	Synthetic process, and crystalline forms of a pyrrolotriazine compound
US7064203B2 (en)	2003-12-29	2006-06-20	Bristol Myers Squibb Company	Di-substituted pyrrolotriazine compounds
MY145634A (en)	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
US7829720B2 (en)	2004-05-04	2010-11-09	Bristol-Myers Squibb Company	Process for preparing atazanavir bisulfate and novel forms
TWI354569B (en)	2004-05-28	2011-12-21	Bristol Myers Squibb Co	Coated tablet formulation and method
US7102002B2 (en)	2004-06-16	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7439246B2 (en) *	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
US7173031B2 (en) *	2004-06-28	2007-02-06	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7432373B2 (en) *	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
TW200600513A (en) *	2004-06-30	2006-01-01	Bristol Myers Squibb Co	A method for preparing pyrrolotriazine compounds
US7253167B2 (en) *	2004-06-30	2007-08-07	Bristol-Myers Squibb Company	Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7102003B2 (en) *	2004-07-01	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
US7504521B2 (en) *	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds
US7148348B2 (en)	2004-08-12	2006-12-12	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US7713973B2 (en) †	2004-10-15	2010-05-11	Takeda Pharmaceutical Company Limited	Kinase inhibitors
US7151176B2 (en) *	2004-10-21	2006-12-19	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
US7514435B2 (en) *	2005-11-18	2009-04-07	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7348325B2 (en) *	2005-11-30	2008-03-25	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
KR101461680B1 (ko)	2005-12-02	2014-11-19	바이엘 헬스케어 엘엘씨	과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
PE20070855A1 (es)	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US8063208B2 (en)	2006-02-16	2011-11-22	Bristol-Myers Squibb Company	Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
WO2009094427A1 (en)	2008-01-23	2009-07-30	Bristol-Myers Squibb Company	4-pyridinone compounds and their use for cancer
WO2010071885A1 (en)	2008-12-19	2010-06-24	Cephalon, Inc.	Pyrrolotriazines as alk and jak2 inhibitors
WO2012031057A1 (en)	2010-09-01	2012-03-08	Bristol-Myers Squibb Company	Bms- 582949 for the treatment of resistant rheumatic disease
CN102153558B (zh) *	2011-02-23	2012-11-21	扬州永济医药新技术有限公司	多靶点抗肿瘤抑制剂2-氨吡咯-三嗪的衍生物及其合成方法
US9724352B2 (en)	2012-05-31	2017-08-08	Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences	Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN103450204B (zh)	2012-05-31	2016-08-17	中国科学院上海药物研究所	吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
CN104003990B (zh) *	2013-02-21	2017-09-15	江苏先声药业有限公司	杂环胺类Hedgehog信号通路抑制剂
US9050345B2 (en)	2013-03-11	2015-06-09	Bristol-Myers Squibb Company	Pyrrolotriazines as potassium ion channel inhibitors
CN104788460B (zh) *	2015-03-27	2016-11-09	陕西师范大学	4-芳氨基吡咯并[2,1-f][1,2,4]三嗪衍生物的制备方法
US11760701B2 (en)	2018-02-27	2023-09-19	The Research Foundation For The State University Of New Yrok	Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
CN108516977A (zh) *	2018-07-10	2018-09-11	刘凤娟	一种用于治疗恶性肿瘤的map激酶抑制剂的合成方法
CN111234067B (zh) *	2018-11-29	2021-08-03	中国石油化工股份有限公司	用于烯烃聚合的固体催化剂组分和催化剂及其应用
CN113372263B (zh) *	2021-05-21	2022-04-19	温州医科大学	一种2-氯-3-胺基萘醌化合物的制备方法
CN113292503B (zh) *	2021-05-22	2022-05-13	台州市第一人民医院	一种2-溴-3-胺基萘醌化合物的制备方法
JP2025512935A (ja)	2022-04-08	2025-04-22	シャイ・セラピューティクス・エルエルシー	がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリータンパク質と相互作用する化合物
CN116789674B (zh) *	2022-08-24	2024-05-24	杭州高光制药有限公司	Nlrp3炎性小体抑制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4908056A (en)	1986-04-25	1990-03-13	E. I. Du Pont De Nemours And Company	Heterocyclic acyl sulfonamides
EP0682027B1 (de)	1994-05-03	1997-10-15	Novartis AG	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
CA2163399A1 (en)	1994-11-24	1996-05-25	Katsuhiro Kawano	Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
US5658903A (en)	1995-06-07	1997-08-19	Smithkline Beecham Corporation	Imidazole compounds, compositions and use
ES2200039T3 (es)	1995-12-08	2004-03-01	Pfizer Inc.	Derivados heterociclicos sustituidos como antagonistas de crf.
ES2205167T3 (es)	1996-01-11	2004-05-01	Smithkline Beecham Corporation	Nuevos compuestos de imidazol sustituidos.
GB9604361D0 (en)	1996-02-29	1996-05-01	Pharmacia Spa	4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
US20010007867A1 (en)	1999-12-13	2001-07-12	Yuhpyng L. Chen	Substituted 6,5-hetero-bicyclic derivatives
ES2273369T3 (es)	1996-08-28	2007-05-01	Pfizer Inc.	Derivados 6,5 heterobiciclicos sustituidos.
US6147080A (en)	1996-12-18	2000-11-14	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
US5945418A (en)	1996-12-18	1999-08-31	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
US6087496A (en)	1998-05-22	2000-07-11	G. D. Searle & Co.	Substituted pyrazoles suitable as p38 kinase inhibitors
PL336990A1 (en)	1997-05-22	2000-07-31	Searle & Co	3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38
US6251914B1 (en)	1997-07-02	2001-06-26	Smithkline Beecham Corporation	Cycloalkyl substituted imidazoles
WO1999024033A1 (en)	1997-11-12	1999-05-20	Shionogi & Co., Ltd.	Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
US6130235A (en)	1998-05-22	2000-10-10	Scios Inc.	Compounds and methods to treat cardiac failure and other disorders
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
IL141724A0 (en)	1998-08-28	2002-03-10	Scios Inc	INHIBITORS OF P38-α KINASE
DK1117653T3 (da)	1998-10-01	2003-05-26	Astrazeneca Ab	Quinolin- og quinazolinderivater og deres anvendelse som inhibitorer af cykokin-merierede sygdomme
GB9906566D0 (en)	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds
ES2258459T3 (es)	1999-05-21	2006-09-01	Bristol-Myers Squibb Company	Pirrolotriazinas inhibidoras de quinasas.
WO2001014378A1 (en)	1999-08-23	2001-03-01	Shionogi & Co., Ltd.	PYRROLOTRIAZINE DERIVATIVES HAVING sPLA2-INHIBITORY ACTIVITIES
GB9924092D0 (en)	1999-10-13	1999-12-15	Zeneca Ltd	Pyrimidine derivatives
IL139197A0 (en)	1999-10-29	2001-11-25	Pfizer Prod Inc	Use of corticotropin releasing factor antagonists and related compositions
MXPA01007019A (es)	1999-11-10	2002-09-18	Johnson & Johnson	2-aril-3-(heteroaril)-imidazo[1,2-a]pirimidinas, sustituidas y composiciones farmaceuticas relacionados y metodos.
US6906067B2 (en)	1999-12-28	2005-06-14	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of TNF-α expression
EP1246823A1 (de)	1999-12-28	2002-10-09	Pharmacopeia, Inc.	Pyrimidin- und triazin kinase-hemmer
US20020065270A1 (en)	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
EP1149583A3 (de)	2000-04-13	2001-11-14	Pfizer Products Inc.	Kombinationen bestehend aus Antagonisten des Corticotropin freisetzenden Faktors und Stoffen, die die Wachstumshormonsekretion fördern
US6518269B1 (en)	2000-07-28	2003-02-11	University Of Arizona Foundation	Cancer treatment
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
DK1363910T3 (da)	2000-11-17	2006-06-26	Bristol Myers Squibb Co	Fremgangsmåder til behandling af P39-kinase-associerede tilstande og pyrrolotriazinforbindelser, der er anvendelige som kinase-inhibitorer
US6670357B2 (en)	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
HUP0401711A3 (en)	2001-06-26	2009-07-28	Bristol Myers Squibb Co	N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them
TW200300350A (en)	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
WO2003091229A1 (en)	2002-04-23	2003-11-06	Bristol-Myers Squibb Company	Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
BR0309669A (pt)	2002-04-23	2005-03-01	Bristol Myers Squibb Co	Compostos de anilina de pirrolo-triazina úteis como inibidores de cinase
US7388009B2 (en)	2002-04-23	2008-06-17	Bristol-Myers Squibb Company	Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
TW200407143A (en)	2002-05-21	2004-05-16	Bristol Myers Squibb Co	Pyrrolotriazinone compounds and their use to treat diseases
US6933386B2 (en)	2002-07-19	2005-08-23	Bristol Myers Squibb Company	Process for preparing certain pyrrolotriazine compounds
TWI329112B (en)	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
US6951859B2 (en)	2002-08-02	2005-10-04	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
TW200420565A (en)	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
BRPI0407282A (pt)	2003-02-05	2006-01-31	Bristol Myers Squibb Co	Processo para preparação de inibidores de pirrolotriazina cinase
US7419978B2 (en)	2003-10-22	2008-09-02	Bristol-Myers Squibb Company	Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
US7102001B2 (en)	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine
MY145634A (en)	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en)	2003-12-29	2006-06-20	Bristol Myers Squibb Company	Di-substituted pyrrolotriazine compounds

2002
- 2002-11-06 US US10/289,010 patent/US6867300B2/en not_active Expired - Fee Related
2003
- 2003-11-03 ES ES03781756T patent/ES2337571T3/es not_active Expired - Lifetime
- 2003-11-03 WO PCT/US2003/035220 patent/WO2004043912A2/en not_active Ceased
- 2003-11-03 CN CNB2003801082297A patent/CN100360532C/zh not_active Expired - Fee Related
- 2003-11-03 AU AU2003287514A patent/AU2003287514A1/en not_active Abandoned
- 2003-11-03 JP JP2004551735A patent/JP4662775B2/ja not_active Expired - Fee Related
- 2003-11-03 EP EP03781756A patent/EP1562949B1/de not_active Expired - Lifetime
- 2003-11-03 DE DE60330800T patent/DE60330800D1/de not_active Expired - Lifetime
- 2003-11-03 CA CA002505365A patent/CA2505365A1/en not_active Abandoned
- 2003-11-03 PL PL377112A patent/PL377112A1/pl not_active Application Discontinuation
- 2003-11-03 AT AT03781756T patent/ATE453645T1/de not_active IP Right Cessation
- 2003-11-03 MX MXPA05004748A patent/MXPA05004748A/es active IP Right Grant
- 2003-11-03 KR KR1020057008063A patent/KR20050084961A/ko not_active Ceased
- 2003-11-03 BR BR0316056-4A patent/BR0316056A/pt not_active IP Right Cessation
- 2003-11-04 TW TW092130839A patent/TWI290555B/zh not_active IP Right Cessation
2004
- 2004-12-22 US US11/019,788 patent/US7211666B2/en not_active Expired - Fee Related
2005
- 2005-05-05 CO CO05043491A patent/CO5560547A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1562949B1 (de)	2009-12-30
TWI290555B (en)	2007-12-01
JP2006514622A (ja)	2006-05-11
CN1735615A (zh)	2006-02-15
US7211666B2 (en)	2007-05-01
JP4662775B2 (ja)	2011-03-30
US6867300B2 (en)	2005-03-15
BR0316056A (pt)	2005-09-27
ES2337571T3 (es)	2010-04-27
AU2003287514A1 (en)	2004-06-03
TW200413382A (en)	2004-08-01
US20050107462A1 (en)	2005-05-19
WO2004043912A2 (en)	2004-05-27
CO5560547A2 (es)	2005-09-30
CN100360532C (zh)	2008-01-09
EP1562949A2 (de)	2005-08-17
PL377112A1 (pl)	2006-01-23
DE60330800D1 (de)	2010-02-11
CA2505365A1 (en)	2004-05-27
US20030186982A1 (en)	2003-10-02
KR20050084961A (ko)	2005-08-29
WO2004043912A3 (en)	2004-07-01
MXPA05004748A (es)	2005-08-03
EP1562949A4 (de)	2007-09-12

Legal Events

Date	Code	Title	Description
2010-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE453645T1 (de)	2010-01-15	Verfahren zur herstellung von pyrrolotriazinverbindungen, die sich als kinaseinhibitoren eignen
ATE425136T1 (de)	2009-03-15	Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen
NO20081941L (no)	2008-04-23	Pyrazol [1,5-alfa]pyrimidinylderivater nyttige som kortikotropin-frigivende faktor (CRF) reseptorantagonister
ATE426594T1 (de)	2009-04-15	Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase
DE60104825D1 (de)	2004-09-16	Verfahren zur herstellung von 6-substituierten (s)-nikotin-derivaten und zwischenverbindungen
ATE537173T1 (de)	2011-12-15	Verfahren zur herstellung von cucurbiturilen
DE60112091D1 (de)	2005-08-25	Verfahren zur herstellung von azacycloalkanoylaminothiazolen
ATE397611T1 (de)	2008-06-15	Verfahren zur herstellung von olanzapin
DE602005026827D1 (de)	2011-04-21	Verfahren zur herstellung von isoindolderivaten
ATE359287T1 (de)	2007-05-15	Ein verfahren zur herstellung von clopidogrel
ATE310735T1 (de)	2005-12-15	Verfahren zur herstellung von spirocyclischen tetronsäurederivaten
ATE496038T1 (de)	2011-02-15	Verfahren zur herstellung von quetiapin
ATE280769T1 (de)	2004-11-15	Verfahren zur herstellung von vitronectin- rezeptorantagonisten
ATE370950T1 (de)	2007-09-15	Verfahren zur herstellung von (1s,4r)-cis-4-(2- amino-6-chlor-9h-purin-9-yl)-2-cyclopenten-1- methanol
DE60234279D1 (de)	2009-12-17	Verfahren zur herstellung eines immunosuppresivums
EP1302459A4 (de)	2004-03-10	Verfahren zur herstellung von annelierten pyrrolen
ATE300534T1 (de)	2005-08-15	Verfahren und zwischenverbindungen zur herstellung von imidazopyridinen
ATE380183T1 (de)	2007-12-15	Verfahren zur herstellung von phenyltetrazolderivaten
DE60306361D1 (de)	2006-08-03	Verfahren zur herstellung von benazeprilhydrochloride
ATE425143T1 (de)	2009-03-15	Verfahren zur herstellung von indolen
ATE403418T1 (de)	2008-08-15	Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid
ATE469119T1 (de)	2010-06-15	Verfahren zur herstellung von polymorphen von sertralin hydrochlorid
ATE413405T1 (de)	2008-11-15	Verfahren zur herstellung von 3- aminothienopyridon-derivaten
ATE405563T1 (de)	2008-09-15	Verfahren zur herstellung von n-substituierten 3beta-aminonortropanen
ATE321028T1 (de)	2006-04-15	Verfahren zur herstellung von 1,3- disubstituierten 2-nitroguanidinen